VSTM2L and rectal cancer: Among these candidate genes, VSTM2L gene was chosen for further investigation because its mRNA expression is significantly relative to both the survival time (OS) and disease-free time (DFS) in the GSE87211 dataset about rectal cancer patients receiving pCRT (Supplementary Figure (available here)).